28,221 Shares in Pulmonx Co. (NASDAQ:LUNG) Bought by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC acquired a new stake in shares of Pulmonx Co. (NASDAQ:LUNG) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 28,221 shares of the company’s stock, valued at approximately $192,000. ADAR1 Capital Management LLC owned 0.07% of Pulmonx at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in LUNG. JPMorgan Chase & Co. increased its position in shares of Pulmonx by 2.4% during the third quarter. JPMorgan Chase & Co. now owns 1,055,522 shares of the company’s stock valued at $8,750,000 after buying an additional 25,002 shares during the period. Geode Capital Management LLC boosted its position in Pulmonx by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 902,240 shares of the company’s stock valued at $6,128,000 after acquiring an additional 9,454 shares in the last quarter. State Street Corp grew its holdings in shares of Pulmonx by 2.6% during the 3rd quarter. State Street Corp now owns 747,028 shares of the company’s stock worth $6,193,000 after acquiring an additional 18,592 shares during the period. Franklin Resources Inc. raised its position in shares of Pulmonx by 2.3% in the 3rd quarter. Franklin Resources Inc. now owns 700,389 shares of the company’s stock worth $5,806,000 after acquiring an additional 15,570 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Pulmonx by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 315,532 shares of the company’s stock worth $2,142,000 after acquiring an additional 2,363 shares in the last quarter. 91.04% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on LUNG. Jefferies Financial Group started coverage on Pulmonx in a research note on Monday, March 10th. They issued a “buy” rating on the stock. Citigroup started coverage on shares of Pulmonx in a report on Monday, March 10th. They set a “buy” rating on the stock. Wells Fargo & Company decreased their price target on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 11th. D. Boral Capital started coverage on shares of Pulmonx in a research report on Monday, March 10th. They set a “buy” rating and a $17.00 price target for the company. Finally, Morgan Stanley began coverage on shares of Pulmonx in a report on Monday, March 10th. They issued an “equal weight” rating on the stock. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $12.75.

Pulmonx Stock Down 2.4 %

NASDAQ:LUNG opened at $6.60 on Tuesday. The firm has a 50-day simple moving average of $7.24 and a two-hundred day simple moving average of $6.88. The firm has a market cap of $262.65 million, a P/E ratio of -4.58 and a beta of 0.61. Pulmonx Co. has a fifty-two week low of $5.46 and a fifty-two week high of $10.01. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.12. The company had revenue of $23.77 million during the quarter, compared to the consensus estimate of $22.29 million. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. Analysts predict that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Glendon E. French III sold 55,453 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $8.28, for a total transaction of $459,150.84. Following the completion of the transaction, the director now directly owns 1,011,974 shares of the company’s stock, valued at $8,379,144.72. The trade was a 5.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Steven S. Williamson sold 27,689 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $7.14, for a total transaction of $197,699.46. Following the completion of the sale, the chief executive officer now owns 194,342 shares in the company, valued at $1,387,601.88. This represents a 12.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 147,986 shares of company stock valued at $1,143,673 over the last ninety days. 5.70% of the stock is currently owned by corporate insiders.

Pulmonx Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.